Soluble gp130 regulatess interleukin-6 in cerebrospinal fluid after subarachnoid haemorrhage

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 9, 2011, Pages 952-954

  Nakura, Takahiro ^a   Osuka, Koji ^a   Inukai, Takashi ^a   Takagi, Teruhide ^a   Takayasu, Masakazu ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN ARTERY ANEURYSM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOPRECIPITATION; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE;

ADULT; AGED; CYTOKINE RECEPTOR GP130; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INTERLEUKIN-6; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; TIME FACTORS;

EID: 80051516000     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.197244     Document Type: Article

References (19)

1. Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid haemorrhage: putative role of inflammation. Neurosurgery 2003;53:123-33.
2. Peterson JW, Kwun BD, Hackett JD, et al. The role of inflammation in experimental cerebral vasospasm. J Neurosurg 1990;72:767-74. (Pubitemid 20146421)
3. Mathiesen T, Andersson B, Loftenius A, et al. Increased interleukin-6 levels in cerebrospinal fluid following subarachnoid hemorrhage. J Neurosurg 1993;78:562-7. (Pubitemid 23099464)
4. Bell MJ, Kochanek PM, Doughty LA, et al. Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J Neurotrauma 1997;14:451-7. (Pubitemid 27338083)
5. Dulkerian SJ, Kilpatrick L, Costarino AT Jr, et al. Cytokine elevations in infants with bacterial and aseptic meningitis. J Pediatr 1995;126:872-6.
6. Michalopoulou M, Nikolaou C, Tavernarakis A, et al. Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases. Immunol Lett 2004;94:183-9. (Pubitemid 38953418)
7. Padberg F, Feneberg W, Schmidt S, et al. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J Neuroimmunol 1999;99:218-23. (Pubitemid 29518234)
8. Fassbender K, Hodapp B, Rossol S, et al. Inflammatory cytokines in subarachnoid hemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry 2001;70:534-7. (Pubitemid 32269696)
9. Osuka K, Suzuki Y, Tanazawa T, et al. Interleukin-6 and development of vasospasm after subarachnoid haemorrhage. Acta Neurochir (Wien) 1998;140:943-51. (Pubitemid 28474664)
10. Schoch B, Regel JP, Wichert M, et al. Analysis of intrathecal interleukin-6 as a potential predictive factor for vasospasm in subarachnoid hemorrhage. Neurosurgery 2007;60:828-36.
11. Osuka K, Watanabe Y, Yamauchi K, et al. Activation of the JAK-STAT signaling pathway in the rat basilar artery after subarachnoid hemorrhage. Brain Res 2006;1072:1-7. (Pubitemid 43255443)
12. Jones SA, Horiuchi S, Topley N, et al. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001;15:43-58. (Pubitemid 32061655)
13. Jostock T, Mullberg J, Ozbek S, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268:160-7. (Pubitemid 32052260)
14. Hans VH, Kossmann T, Joller H, et al. Interleukin-6 and its soluble receptor in serum and cerebrospinal fluid after cerebral trauma. Neuroreport 1999;10:409-12. (Pubitemid 29104822)
15. Acalovschi D, Wiest T, Hartmann M, et al. Multiple levels of regulation of the interleukin-6 system in stroke. Stroke 2003;34:1864-9. (Pubitemid 36944770)
16. Tarkowski E, Rosengren L, Blomstrand C, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995;26:1393-8.
17. Richards PJ, Nowell MA, Horiuchi S, et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum 2006;54:1662-72.
18. Nowell MA, Richards PJ, Horiuchi S, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003;171:3202-9. (Pubitemid 37093546)
19. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-8. (Pubitemid 30305911)